Bio-Works Technologies
Bio-Works receives WorkBeads order worth SEK 2.5 million
REG
The customer is a global contract development and manufacturing organization (CDMO) focused on peptide- and oligonucleotide-based therapies.
“The order from a returning global CDMO confirms our strong position in the purification of peptide- and oligonucleotide-based pharmaceuticals. It is a clear sign that Bio-Works delivers solutions that meet the highest standards of quality and performance,” says Lone Carlbom, CEO of Bio-Works.
This disclosure contains information that Bio-Works Technologies AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 15-05-2025 15:02 CET.
| Datum | 2025-05-15, kl 15:02 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!